Key February 2025 alert for the cosmetics industry: new EU rules restrict ingredients like Genistein, Kojic Acid, and Alpha-Arbutin under Annex III and ban specific nanomaterials under Annex II.

Key February 2025 alert for the cosmetics industry: new EU rules restrict ingredients like Genistein, Kojic Acid, and Alpha-Arbutin under Annex III and ban specific nanomaterials under Annex II.
Discover the information that must be visible on the labels of cosmetic products under article 19 of the EU Cosmetics Regulation.
Learn about the new Article 10a under EU MDR and IVDR, requiring manufacturers to notify authorities and stakeholders of potential medical device or IVD supply interruptions. Understand the scope, notification process, and exemptions, as well as how to comply with these regulations to ensure patient safety and continuity of care.
Discover the new EU General Product Safety Regulation (GPSR) requirements effective 13 December 2024. Learn about the role of Responsible Person and Authorised Representative (EAR) to ensure product compliance in the EU market.
Distance sales devices, sold through online platforms, must meet specific regulations outlined in Article 6 of the MDR and IVDR to ensure safety and performance. This includes devices used for remote healthcare services, even if not directly sold within the EU.
Discover how the EU and Switzerland maintain strong trade relations through mutual regulation agreements, enabling smoother market access for many products.
From 13 December 2024, the new EU General Product Safety Regulation (GPSR) applies, requiring stricter safety measures and a Responsible Person for all products.
Ensure your medical devices remain compliant by the upcoming 26 September 2024 deadline. Manufacturers must finalize agreements with notified bodies for MDR CE Certification to retain the legacy status of their devices.
On 9 July 2024, the Official Journal of the EU published Regulation (EU) 2024/1860, amending the medical devices Regulations (MDR and IVDR). This introduces an extended legacy period for IVDs, effective immediately.
To market medical devices in the EU, manufacturers must provide clinical data specific to the European population.